Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Atea Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tenax Therapeutics (TENX – Research Report) and Atea...

Current Quarter	$-0.48	Next Quarter	$-0.53
Current Year	$-1.73	Next Year	$-1.75
QoQ Growth	-10.4%	YoY Growth	-1.2%
3Y EPS CAGR	-49.9%	Target Price	$6.00
Consensus	Buy	Upside	+102.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVIR	$2.97	-1.00%	568.12K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AVIR	$2.97	-1.0%	568.12K
3
4
5
6

AVIR

AVIR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Atea Pharmaceuticals Inc. Data in Excel

Get Atea Pharmaceuticals Inc. Data in Excel